Pharmaceutical company AstraZeneca is reportedly in discussions over a potential merger with Bristol Myers Squibb in what could become one of the largest healthcare deals in history.

Industry sources said the combined company would strengthen its leadership in cancer treatments, cardiovascular medicine and biotechnology research.

Although discussions are still at an early stage, analysts said the proposed transaction could reshape the global pharmaceutical industry by combining two major research pipelines and expanding access to key international markets.

Investors are closely watching developments because of the potential scale of the transaction.

Some shareholders have expressed concerns about the size of the proposed merger, including possible regulatory challenges and the integration of two large multinational businesses.

However, supporters argue that combining research capabilities could accelerate the development of new medicines and improve long-term competitiveness.

Healthcare analysts noted that large pharmaceutical companies continue exploring mergers and acquisitions to strengthen product portfolios as patents on existing medicines expire and competition increases.

Strategic partnerships have become increasingly important in maintaining long-term growth.

If negotiations progress, the proposed merger would require approval from shareholders and regulators in several countries.

Industry observers believe any final agreement would attract close scrutiny because of its potential impact on competition within the global pharmaceutical sector.

Source: Financial Times